Titan Pharmaceuticals, Inc.

TTNP

US8883147055

Pharmaceuticals

Delayed Nasdaq Other stock markets 15:21:14 23/05/2024 BST			5-day change	1st Jan Change
6.718 ^USD	+0.64%		+3.66%	-18.57%

04-01	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-26	Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	MT

Titan Pharmaceuticals, Inc. Announces Retirement of Eurelio Cavalier from its Board

February 27, 2017 at 11:11 am

On February 23, 2017, Titan Pharmaceuticals, Inc. announced that Mr. Eurelio Cavalier that he will be retiring from the company’s board of directors at the end of the month.

Latest news about Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	01-26	MT
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024	01-18	CI
Titan Pharmaceuticals to Implement 1-for-20 Reverse Stock Split	12-29	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Titan Pharmaceuticals, Inc. Announces Board Changes	16/10/23	CI
Titan Pharmaceuticals Appoints New Chairman of the Board	16/10/23	MT
Titan Pharmaceuticals, Inc. Announces Board Resignations	19/09/23	CI
Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd	12/09/23	CI
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc..	31/08/23	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. for $52 million.	26/07/23	CI
Titan Pharmaceuticals, Inc. Announces Board Changes	07/07/23	CI
Insider Sell: Titan Pharmaceuticals	23/06/23	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Titan Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Sector Update: Health Care Stocks Sink on Thursday	15/12/22	MT
Sector Update: Health Care	15/12/22	MT
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop	15/12/22	MT
Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022	15/12/22	CI
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US	12/12/22	MT
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc	12/12/22	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Declaration of Voting Results by Titan Pharmaceuticals, Inc	16/08/22	CI

Chart Titan Pharmaceuticals, Inc.

Duration

Period

More charts

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Sector

Pharmaceuticals

Calendar

10/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TITAN PHARMACEUTICALS, INC.	-18.57%	6.1M
ELI LILLY AND COMPANY	+38.20%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.62%	369B
MERCK & CO., INC.	+20.07%	332B
ABBVIE INC.	+2.53%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.26%	168B

Other Pharmaceuticals